Initial data from Phase I clinical trial evaluating CD16-CR used in combination with rituximab (anti CD20) in adult patients with relapsed/refractory non-Hodgkin lymphoma suggest that CD16-CR T cells can achieve tumor reduction even a low dose, without provoking cytokines release syndrome (CRS) or neurotoxicity. This evidence concerns the gene FCGR3A and non-Hodgkin lymphoma.